Trial Profile

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Subcutaneous Dose of GenSci098 in Patients With Graves' Disease

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 23 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Dec 2025 New trial record
15 Dec 2025 According to a Changchun GeneScience Pharmaceutical media release, company will receive up to 1.365 billion dollars in total, including near-term development milestones and additional development, regulatory, and commercial milestone payments, under an exclusive global ex-China license agreement for GS-098, which will be developed as YB-101 outside of China for the treatment of Grave's disease (GD) and thyroid eye disease (TED).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com